JP2021526796A5 - - Google Patents

Info

Publication number
JP2021526796A5
JP2021526796A5 JP2020567764A JP2020567764A JP2021526796A5 JP 2021526796 A5 JP2021526796 A5 JP 2021526796A5 JP 2020567764 A JP2020567764 A JP 2020567764A JP 2020567764 A JP2020567764 A JP 2020567764A JP 2021526796 A5 JP2021526796 A5 JP 2021526796A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutically acceptable
antisense oligomer
acceptable salt
oligomer according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020567764A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/036764 external-priority patent/WO2019241385A2/en
Publication of JP2021526796A publication Critical patent/JP2021526796A/ja
Publication of JP2021526796A5 publication Critical patent/JP2021526796A5/ja
Priority to JP2024096569A priority Critical patent/JP2024116362A/ja
Withdrawn legal-status Critical Current

Links

JP2020567764A 2018-06-13 2019-06-12 筋ジストロフィーに対するエクソンスキッピングオリゴマー Withdrawn JP2021526796A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024096569A JP2024116362A (ja) 2018-06-13 2024-06-14 筋ジストロフィーに対するエクソンスキッピングオリゴマー

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862684615P 2018-06-13 2018-06-13
US62/684,615 2018-06-13
US201962860446P 2019-06-12 2019-06-12
US62/860,446 2019-06-12
PCT/US2019/036764 WO2019241385A2 (en) 2018-06-13 2019-06-12 Exon skipping oligomers for muscular dystropy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024096569A Division JP2024116362A (ja) 2018-06-13 2024-06-14 筋ジストロフィーに対するエクソンスキッピングオリゴマー

Publications (2)

Publication Number Publication Date
JP2021526796A JP2021526796A (ja) 2021-10-11
JP2021526796A5 true JP2021526796A5 (cg-RX-API-DMAC7.html) 2022-06-13

Family

ID=68843196

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567764A Withdrawn JP2021526796A (ja) 2018-06-13 2019-06-12 筋ジストロフィーに対するエクソンスキッピングオリゴマー
JP2024096569A Pending JP2024116362A (ja) 2018-06-13 2024-06-14 筋ジストロフィーに対するエクソンスキッピングオリゴマー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024096569A Pending JP2024116362A (ja) 2018-06-13 2024-06-14 筋ジストロフィーに対するエクソンスキッピングオリゴマー

Country Status (3)

Country Link
US (2) US20220251551A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021526796A (cg-RX-API-DMAC7.html)
WO (1) WO2019241385A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US20250228954A1 (en) * 2020-01-24 2025-07-17 Sarepta Therapeutics, Inc. Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning
PE20230237A1 (es) 2020-02-28 2023-02-07 Nippon Shinyaku Co Ltd Acidos nucleicos antisentido que inducen la omision del exon 51
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3978608A1 (en) * 2020-10-05 2022-04-06 SQY Therapeutics Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
CN118401553A (zh) * 2021-07-09 2024-07-26 达因疗法公司 肌肉靶向复合物及其用于治疗肌养蛋白病的用途
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
AU2023245901A1 (en) * 2022-03-30 2024-10-03 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627917T3 (es) * 2004-06-28 2017-08-01 The University Of Western Australia Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
NZ584793A (en) * 2007-10-26 2012-05-25 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
WO2009101399A1 (en) * 2008-02-12 2009-08-20 Isis Innovation Limited Treatment of muscular dystrophy using peptide nucleic acid ( pna)
EP3133160B1 (en) * 2008-10-24 2018-12-12 Sarepta Therapeutics, Inc. Exon skipping compositions for dmd
SI2607484T1 (sl) * 2008-10-27 2016-11-30 Biomarin Technologies B.V. Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
CN102459595A (zh) * 2009-04-24 2012-05-16 普罗森那技术公司 用于治疗dmd的包含肌苷的寡核苷酸
HUE040445T2 (hu) * 2009-11-12 2019-03-28 Univ Western Australia Antiszensz molekulák és eljárások betegségek kezelésére
BR112013020273A2 (pt) * 2011-02-08 2016-10-18 Charlotte Mecklenburg Hospital oligonucleotídeos antissenso
AU2011367230B2 (en) * 2011-05-05 2017-08-10 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA2862628C (en) * 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
US9217148B2 (en) * 2013-03-14 2015-12-22 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
HK1220154A1 (zh) * 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
JP2018530560A (ja) * 2015-10-09 2018-10-18 サレプタ セラピューティクス, インコーポレイテッド デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
MA45158A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Composition pharmaceutique comprenant de l'éteplirsen
US20190330626A1 (en) * 2016-07-15 2019-10-31 Ionis Pharmaceuticals, Inc. Compounds and methods for use in dystrophin transcript
GB201711809D0 (en) * 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide

Similar Documents

Publication Publication Date Title
US10927378B2 (en) Compound and method for treating myotonic dystrophy
JP2024532465A5 (cg-RX-API-DMAC7.html)
JP2023123491A5 (cg-RX-API-DMAC7.html)
Egholm et al. Recognition of guanine and adenine in DNA by cytosine and thymine containing peptide nucleic acids (PNA)
CN103998458B (zh) 具有中央疏水域的细胞穿透肽
JP2019514426A5 (cg-RX-API-DMAC7.html)
JP2024518068A5 (cg-RX-API-DMAC7.html)
JP2022513719A5 (cg-RX-API-DMAC7.html)
JP2014515762A5 (cg-RX-API-DMAC7.html)
JP2010505741A5 (cg-RX-API-DMAC7.html)
JP2012506703A5 (cg-RX-API-DMAC7.html)
JP2021500064A5 (cg-RX-API-DMAC7.html)
JP2018530560A5 (cg-RX-API-DMAC7.html)
JP2021526017A5 (cg-RX-API-DMAC7.html)
Dragulescu-Andrasi et al. Cell-permeable GPNA with appropriate backbone stereochemistry and spacing binds sequence-specifically to RNA
JP2012515172A5 (cg-RX-API-DMAC7.html)
JP2024518476A5 (cg-RX-API-DMAC7.html)
JP2012505250A5 (cg-RX-API-DMAC7.html)
CN107074911B (zh) 肽核酸单体和低聚体
JP2021534131A5 (cg-RX-API-DMAC7.html)
JP2024524291A5 (cg-RX-API-DMAC7.html)
MX2024005883A (es) Compuesto para el secuestro de anticuerpos no deseables en un paciente.
JP2022511055A5 (cg-RX-API-DMAC7.html)
EP1480657A1 (en) Polymers for delivering peptides and small molecules i in vivo /i
JP2023554379A5 (cg-RX-API-DMAC7.html)